Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer

Background: The PI3K/AKT/mTOR pathway is an important oncogenic driver in triple-negative breast cancer (TNBC). This study investigated the clinical efficacy and safety of the combination of gemcitabine and cisplatin with everolimus (GPE) in patients with metastatic TNBC. Methods: In phase I, we ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, In Hae, Kong, Sun-Young, Kwon, Youngmee, Kim, Min Kyeong, Sim, Sung Hoon, Joo, Jungnam, Lee, Keun Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907662/
https://www.ncbi.nlm.nih.gov/pubmed/29675095
http://dx.doi.org/10.7150/jca.24035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907662/
https://www.ncbi.nlm.nih.gov/pubmed/29675095
http://dx.doi.org/10.7150/jca.24035

Ejemplares similares